US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

AI Healthcare

750.40

+42.405.99%

Number of Gainers:4

Number of Losers:- -

Number of Flat:- -

PE:- -

High:755.84

Open:702.94

Low:702.94

Close:708.00

Volume:43.79M

Turnover:1.43B

Market Cap:23.82B

Float Cap:18.46B

Loading ...

Tempus AI Inc Stock (TEM) Moved Up by 8.36% on Aug 21: Drivers Behind the Movement

Tempus AI CFO James William Rogers Disposes of USD 2.7 Million in Common Shares

Tempus AI Inc Stock (TEM) Moved Up by 10.87% on Aug 20: What Signal Does It Send?

Tempus AI up over 22%, on Pace for Largest Percent Increase Since January 2025

Tempus AI Stock (TEM) Is Surging 24% on Wednesday – Here’s Why

Tempus AI rises 20.1%

tempus AI Inc Class A call volume above normal and directionally bullish

Tempus AI Director Nadja West Disposes of 3,000 Common Shares Worth $161,700

Contineum, Disc Medicine, Recursion Advance Pipelines Ahead of Catalysts, Morgan Stanley Says

MT Newswires Live

Morgan Stanley Adjusts PT on Recursion Pharmaceuticals to $5.30 From $5.50, Keeps Equalweight Rating

MT Newswires Live

Tempus AI CEO Data Ryan Fukushima Disposes of 20.000 Shares Worth $1 Juta

Tempus AI (TEM) After CellCarta Deal And PRISM2 Validation Faces A Fresh Valuation Test

Simply Wall St.

Why Tempus AI (TEM) Is Up 18.6% After Joining CellCarta’s CDx Commercialization Lab Network

Simply Wall St.

Analysts Offer Insights on Healthcare Companies: Beam Therapeutics (BEAM), OmniAb (OABI) and Astrana Health (ASTH)

Recursion Director Blake Borgeson Disposes of 30,000 Shares for $97,500

Oculis Q2 Net Loss Narrows Despite Higher Expenses

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/BK4611/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4611","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4611\",,,,,undefined,":{"symbol":"BK4611","market":"US","secType":"PLATE","nameCN":"AI Healthcare","latestPrice":750.3989,"timestamp":1787342399999,"preClose":707.9952,"halted":0,"volume":43791257,"delay":0,"changeRate":0.059893,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Market Closed","change":42.403748,"latestTime":"08-21 16:00:00 EDT","open":702.9417,"high":755.8414,"low":702.9417,"amount":1430174463.255378,"amplitude":0.074718,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787558400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":5.336407,"peRate":-16.990339,"turnoverRate":0.053268,"increases":4,"decrements":0,"flats":0,"marketCap":23815353344,"floatMarketCap":18456993920},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4611\",,,,,undefined,":{"symbol":"BK4611","high":755.8414,"amplitude":0.074718,"preClose":707.9952,"low":702.9417,"pbRate":"5.336407","latestPrice":750.3989,"volume":43791257,"delay":0,"open":702.9417,"prevYearClose":658.3995,"prevWeekClose":611.922,"prevMonthClose":543.3925,"prevQuarterClose":681.0329,"fiveDayClose":611.922,"twentyDayClose":530.0387,"sixtyDayClose":610.5186,"secType":"PLATE","market":"US","turnoverRate":0.053268,"peRate":-16.990339,"marketCap":23815353344,"floatMarketCap":18456993920,"timestamp":1787342399999,"nameCN":"AI Healthcare"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4611\",,,,undefined,":{"bkCode":"BK4611","up":4,"down":0,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4611\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2661292406","title":"Tempus AI Inc Stock (TEM) Moved Up by 8.36% on Aug 21: Drivers Behind the Movement","url":"https://stock-news.laohu8.com/highlight/detail?id=2661292406","media":"TradingKey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661292406?lang=en_us&edition=fundamental","pubTime":"2026-08-22 02:15","pubTimestamp":1787336125,"startTime":"0","endTime":"0","summary":"• Tempus AI rose due to analyst upgrades and precision oncology expansion.\n• Second-quarter results showed improved gross margins and positive net income.\n• Technical indicators show a buy signal alongside overbought conditions.","market":"us","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/news/market-movers/262125151-market-movers-tem-20260821","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HEAL","BK4611","TEMC","ARKG","LU1861559042.SGD","LU1861558580.USD","BK4121","BK4613","TEMT","TEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661351255","title":"Tempus AI CFO James William Rogers Disposes of USD 2.7 Million in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2661351255","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661351255?lang=en_us&edition=fundamental","pubTime":"2026-08-21 09:00","pubTimestamp":1787274055,"startTime":"0","endTime":"0","summary":"Tempus AI CFO James William Rogers disposes of USD 2.7 million in common sharesTempus AI CFO James William Rogers sold 48,842 Class A common shares on Aug. 18-19, 2026.Sale prices were USD 49.61 per s","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nNDL9MQ6Ty:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Tempus AI CFO James William Rogers Disposes of USD 2.7 Million in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4611","LU1861559042.SGD","LU1861558580.USD","BK4613","ARKG","TEM","BK4121","TEMT","HEAL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661235022","title":"Tempus AI Inc Stock (TEM) Moved Up by 10.87% on Aug 20: What Signal Does It Send?","url":"https://stock-news.laohu8.com/highlight/detail?id=2661235022","media":"TradingKey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661235022?lang=en_us&edition=fundamental","pubTime":"2026-08-21 00:15","pubTimestamp":1787242518,"startTime":"0","endTime":"0","summary":"• Merck and Moderna released favorable Phase 3 trial results for individualized mRNA cancer vaccines.\n• BTIG Research reaffirmed a Buy rating and raised Tempus AI's price target.\n• Tempus AI reported strong revenue expansion, gross margins, and raised full-year guidance.","market":"other","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/news/market-movers/262121723-market-movers-tem-20260820","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TEMT","ARKG","LU1861558580.USD","HEAL","TEM","LU1861559042.SGD","BK4611","BK4613","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660271724","title":"Tempus AI up over 22%, on Pace for Largest Percent Increase Since January 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2660271724","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660271724?lang=en_us&edition=fundamental","pubTime":"2026-08-20 01:57","pubTimestamp":1787162220,"startTime":"0","endTime":"0","summary":"Tempus AI, Inc. Class A  is currently at $60.29, up $10.93 or 22.14%--Would be highest close since July 9, 2026, when it closed at $61.50--On pace for largest percent increase since Jan. 21, 2025, when it rose 35.53%--Snaps a five day losing streak--Up 37.43% month-to-date--Up 2.1% year-to-date--Down 41.61% from its all-time closing high of $103.25 on Oct. 8, 2025--Down 17.73% from 52 weeks ago , when it closed at $73.28--Down 41.61% from its 52-week closing high of $103.25 on Oct. 8, 2025--Up 45.1% from its 52-week closing low of $41.55 on July 29, 2026--Traded as high as $61.40; highest intraday level since July 10, 2026, when it hit $62.95--Up 24.39% at today's intraday high; largest intraday percent increase since Jan. 21, 2025, when it rose as much as 41.76%All data as of 1:53:34 PM ETSource: Dow Jones Market Data, FactSet","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","TEM","BK4611","ARKG","HEAL","BK4613","TEMT","LU1861558580.USD","LU1861559042.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660042204","title":"Tempus AI Stock (TEM) Is Surging 24% on Wednesday – Here’s Why","url":"https://stock-news.laohu8.com/highlight/detail?id=2660042204","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660042204?lang=en_us&edition=fundamental","pubTime":"2026-08-20 01:04","pubTimestamp":1787159095,"startTime":"0","endTime":"0","summary":"Tempus AI ($TEM) surged nearly 24% on Wednesday after a major Phase 3 cancer vaccine update from Merck ($MRK) and Moderna ($MRNA). The news instant...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/tempus-ai-stock-tem-is-surging-24-on-wednesday-heres-why?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/tempus-ai-stock-tem-is-surging-24-on-wednesday-heres-why?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4611","LU1861558580.USD","TEM","ARKG","BK4121","HEAL","TEMT","LU1861559042.SGD","BK4613"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2660422382","title":"Tempus AI rises 20.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660422382","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660422382?lang=en_us&edition=fundamental","pubTime":"2026-08-20 00:05","pubTimestamp":1787155531,"startTime":"0","endTime":"0","summary":"Tempus AI (TEM) is up 20.1%, or $9.94 to $59.30. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial ne...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tempus-ai-rises-20-1-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tempus-ai-rises-20-1-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4613","TEM","HEAL","BK4611","TEMT","LU1861559042.SGD","BK4121","ARKG","LU1861558580.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660424234","title":"tempus AI Inc Class A call volume above normal and directionally bullish","url":"https://stock-news.laohu8.com/highlight/detail?id=2660424234","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660424234?lang=en_us&edition=fundamental","pubTime":"2026-08-19 23:45","pubTimestamp":1787154309,"startTime":"0","endTime":"0","summary":"Bullish option flow detected in tempus AI (TEM) Inc Class A with 47,702 calls trading, 8x expected, and implied vol increasing almost 12 points to ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tempus-ai-inc-class-a-call-volume-above-normal-and-directionally-bullish-thefly-news-4?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tempus-ai-inc-class-a-call-volume-above-normal-and-directionally-bullish-thefly-news-4?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4121","BK4611","LU1861559042.SGD","LU1861558580.USD","TEMT","BK4613","TEM","ARKG","HEAL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660940894","title":"Tempus AI Director Nadja West Disposes of 3,000 Common Shares Worth $161,700","url":"https://stock-news.laohu8.com/highlight/detail?id=2660940894","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660940894?lang=en_us&edition=fundamental","pubTime":"2026-08-19 04:16","pubTimestamp":1787084176,"startTime":"0","endTime":"0","summary":"Tempus AI director Nadja West disposes of 3,000 common shares worth $161,700Tempus AI director Nadja West sold 3,000 shares of Class A common stock on Aug. 14, 2026 at $53.9.Post-transaction holdings ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260818:nNDL6wtwZX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Tempus AI Director Nadja West Disposes of 3,000 Common Shares Worth $161,700","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1861558580.USD","TEMT","BK4613","ARKG","HEAL","BK4121","BK4611","TEM","LU1861559042.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660435025","title":"Contineum, Disc Medicine, Recursion Advance Pipelines Ahead of Catalysts, Morgan Stanley Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2660435025","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660435025?lang=en_us&edition=fundamental","pubTime":"2026-08-17 23:01","pubTimestamp":1786978897,"startTime":"0","endTime":"0","summary":"Contineum Therapeutics , Disc Medicine , and Recursion Pharmaceuticals  are making meaningful pipeline progress, with key clinical and regulatory catalysts ahead in 2026, Morgan Stanley said in a note Monday.Contineum had a solid Q2, with the company advancing PIPE-791 toward a potentially large idiopathic pulmonary fibrosis opportunity, backed by strong trial progress, better tolerability, additional chronic-pain potential, and enough cash to fund operations through mid-2029, the investment firm said.Morgan Stanley said Disc Medicine is seeing \"very strong\" demand for bitopertin, with its expanded access program launched ahead of a phase 3 trial readout expected in Q4. Management says demand is currently limited by operational bandwidth, not patient interest, according to the note.Recursion Pharmaceuticals is showing growing validation of its artificial intelligence drug-discovery platform, the firm said. The company cut its 2026 cash spending forecast to about $375 million from rough","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RXRX","CTNM","BK4611","BK4139","BK4609","BK4539","BK4548","LU0053671581.USD","BK4007","IRON"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660489363","title":"Morgan Stanley Adjusts PT on Recursion Pharmaceuticals to $5.30 From $5.50, Keeps Equalweight Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2660489363","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660489363?lang=en_us&edition=fundamental","pubTime":"2026-08-17 17:54","pubTimestamp":1786960445,"startTime":"0","endTime":"0","summary":"Recursion Pharmaceuticals (RXRX) has an average rating of overweight and mean price target of $7.22, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic researc","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4548","BK4139","BK4611","RXRX","BK4609","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658946487","title":"Tempus AI CEO Data Ryan Fukushima Disposes of 20.000 Shares Worth $1 Juta","url":"https://stock-news.laohu8.com/highlight/detail?id=2658946487","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658946487?lang=en_us&edition=fundamental","pubTime":"2026-08-12 05:30","pubTimestamp":1786483817,"startTime":"0","endTime":"0","summary":"Tempus AI CEO Data Ryan Fukushima disposes of 20.000 shares worth $1 jutaTempus AI Inc.: Ryan Fukushima, CEO, Data, melaporkan penjualan 20.000 saham Class A pada 7 Agustus 2026.Saham dijual pada harg","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nNDL65Rs5B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Tempus AI CEO Data Ryan Fukushima Disposes of 20.000 Shares Worth $1 Juta","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HEAL","TEM","BK4613","LU1861558580.USD","ARKG","BK4611","BK4121","LU1861559042.SGD","TEMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658670176","title":"Tempus AI (TEM) After CellCarta Deal And PRISM2 Validation Faces A Fresh Valuation Test","url":"https://stock-news.laohu8.com/highlight/detail?id=2658670176","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658670176?lang=en_us&edition=fundamental","pubTime":"2026-08-10 00:30","pubTimestamp":1786293017,"startTime":"0","endTime":"0","summary":"Tempus AI (TEM) is back in focus after CellCarta added the company to its CDx Commercialization Lab Network, linking Tempus Hub ordering to CellCarta testing and tightening access to oncology companion diagnostics for U.S. providers.\nSee our latest analysis for Tempus AI.\nTempus AI’s recent CellCarta partnership, PRISM2 publication and earnings update have arrived alongside a sharp 1-day share price return of 12.86% and a 7-day share price return of 18.65%. However, the year-to-date share...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tem/tempus-ai/news/tempus-ai-tem-after-cellcarta-deal-and-prism2-validation-fac","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tem/tempus-ai/news/tempus-ai-tem-after-cellcarta-deal-and-prism2-validation-fac","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["TEM","LU1861559042.SGD","BK4611","BK4121","BK4613","ARKG","HEAL","LU1861558580.USD","TEMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657845678","title":"Why Tempus AI (TEM) Is Up 18.6% After Joining CellCarta’s CDx Commercialization Lab Network","url":"https://stock-news.laohu8.com/highlight/detail?id=2657845678","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657845678?lang=en_us&edition=fundamental","pubTime":"2026-08-08 20:31","pubTimestamp":1786192260,"startTime":"0","endTime":"0","summary":"On 6 August 2026, CellCarta Inc. said it would add Tempus AI to its CDx Commercialization Lab Network, with Tempus using its Tempus Hub to manage provider test ordering, sample routing to CellCarta, and result delivery for oncology-focused companion diagnostics in the U.S.\nThis collaboration links Tempus AI’s ordering and data platform with CellCarta’s development and regulatory capabilities, aiming to close the gap between CDx approval and real-world clinical access for cancer...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tem/tempus-ai/news/why-tempus-ai-tem-is-up-186-after-joining-cellcartas-cdx-com","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tem/tempus-ai/news/why-tempus-ai-tem-is-up-186-after-joining-cellcartas-cdx-com","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["HEAL","BK4613","LU1861559042.SGD","LU1861558580.USD","TEM","BK4121","ARKG","TEMT","BK4611"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657433647","title":"Analysts Offer Insights on Healthcare Companies: Beam Therapeutics (BEAM), OmniAb (OABI) and Astrana Health (ASTH)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657433647","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657433647?lang=en_us&edition=fundamental","pubTime":"2026-08-07 23:50","pubTimestamp":1786117814,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Beam Therapeutics (BEAM), OmniAb (OABI) and Astrana ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-beam-therapeutics-beam-omniab-oabi-and-astrana-health-asth-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-beam-therapeutics-beam-omniab-oabi-and-astrana-health-asth-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1861558580.USD","BK4585","BK4505","BK4581","LU0128526141.USD","BK4121","OABI","LABU","ASTH","BK4139","BK4588","BK4556","BK4137","XBI","BK4196","BK4535","LU0029874061.USD","BK4611","HCSG","BEAM","LU1861559042.SGD","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657665036","title":"Recursion Director Blake Borgeson Disposes of 30,000 Shares for $97,500","url":"https://stock-news.laohu8.com/highlight/detail?id=2657665036","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657665036?lang=en_us&edition=fundamental","pubTime":"2026-08-07 05:24","pubTimestamp":1786051497,"startTime":"0","endTime":"0","summary":"Recursion director Blake Borgeson disposes of 30,000 shares for $97,500Recursion Pharmaceuticals director Blake Borgeson sold 30,000 Class A common shares on Aug. 4 at $3.25.Direct holdings fell to 6,","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL9pSDDB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Recursion Director Blake Borgeson Disposes of 30,000 Shares for $97,500","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4611","BK4609","RXRX","BK4139","BK4548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657668929","title":"Oculis Q2 Net Loss Narrows Despite Higher Expenses","url":"https://stock-news.laohu8.com/highlight/detail?id=2657668929","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657668929?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:32","pubTimestamp":1786048350,"startTime":"0","endTime":"0","summary":"Oculis Q2 net loss narrows despite higher expensesOverviewBiopharma firm's Q2 net loss narrowed yr/yr as operating expenses roseOperating expenses increased, mainly from higher headcount and share-bas","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4431F0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1861558580.USD","LU1861559042.SGD","ALGS","CRSP","BK4611","OCS","ARKG","BK4556","BK4585","BK4007","BK4505","BK4139","BK4588"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":16,"code":"91000000","status":"200"}]}}